文献速递头颈部肿瘤放疗

多中心调查揭示新冠疫情期间头颈肿瘤标准治疗与调整的差异

A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-06-30

英国NCRI头颈临床研究组开展多中心问卷调查,评估新冠前头颈肿瘤标准实践及第一波疫情期间的治疗调整。30家中心中23家(76.7%)回复,21家(91%)至少有一项治疗调整,主要表现为根治性放疗改为大分割或加速方案、术后放疗大分割、新辅助化疗停止及 concurrent 化疗选择性省略。调查显示各中心标准实践与疫情调整存在差异,需及时形成共识。

要点

  • 23/30家中心回复,21家(91%)至少一项治疗调整。
  • 15家(65%)根治性放疗改为大分割或加速方案。
  • 17家(73.9%)一线化疗改为帕博利珠单抗。

核心结论

  • 新冠疫情期间头颈肿瘤标准实践与治疗调整存在中心间差异。
  • 需及时形成英国及其他国家头颈肿瘤管理共识。

研究设计与样本

  • 英国NCRI头颈临床研究组发起的多中心问卷调查。
  • 调查30家中心,23家(76.7%)回复并纳入分析。

主要发现

  • 21家(91%)参与中心至少有一项治疗调整。
  • 15家(65%)中心改变根治性放疗为大分割或加速方案。
  • 10家(43.5%)中心术后放疗改为大分割方案。
  • 12家(52.2%)中心对所有患者停止新辅助化疗。
  • 13家(56.5%)中心对同步放化疗患者选择性省略化疗。

关键数值与推荐

  • 17家(73.9%)中心根据NHS England临时指南将一线化疗改为帕博利珠单抗。
  • 8家(34.8%)中心对已接受系统治疗患者提前停止或延迟治疗。
  • 多数中心在手术、影像、组织病理和牙科筛查方面无显著变化。

临床怎么用

  • 疫情期间头颈肿瘤治疗调整以大分割放疗、选择性省略化疗及免疫治疗替代为主。
  • 各中心实践差异提示需参考共识或指南以减少变异。

局限性

  • 调查仅覆盖英国中心,结果外推需谨慎。
  • 问卷回复率为76.7%,未回复中心情况未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The onset of the COVID-19 pandemic necessitated rapid changes to the practice of head and neck oncology in UK. There was a delay between the onset of the pandemic and the release of guidelines from cancer societies and networks, leading to a variable response of individual centres. This survey was conducted to assess the pre-Covid-19 pandemic standard of practice for head and neck oncology patients and the treatment modifications introduced during the first wave of the pandemic in UK. METHODOLOGY: The UK National Cancer Research Institute (NCRI) Head and Neck Clinical Studies Group initiated a multi-centre survey using questionnaire to investigate the effect on feeding tube practice, radiotherapy (RT) fractionation and volumes, use of chemotherapy in the neo-adjuvant, concurrent and palliative setting, the use of immunotherapy in the palliative setting, access to radiology and histopathology services, and availability of surgical procedures. RESULTS: 30 centres were approached across UK; 23 (76.7%) centres responded and were included in the survey. There were differences in the standard practices in feeding tube policy, RT dose and fractionation as well as concurrent chemotherapy use. 21 (91%) participating centres had at least one treatment modification. 15 (65%) centres initiated a change in radical RT; changing to either a hypofractionation or acceleration schedule. For post-operative RT 10 centres (43.5%) changed to a hypofractionation schedule. 12 (52.2%) centres stopped neo-adjuvant chemotherapy for all patients; 13 (56.5%) centres followed selective omission of chemotherapy in concurrent chemo-radiotherapy patients, 17 (73.9%) centres changed first-line chemotherapy treatment to pembrolizumab (following NHS England's interim guidance) and 8 (34.8%) centres stopped the treatment early or offered delays for patients that have been already on systemic treatment. The majority of centres did not have significant changes associated with surgery, radiology, histopathology and dental screening. CONCLUSION: There are variations in the standard of practice and treatment modifications for head and neck cancer patients during Covid-19 pandemic. A timely initiative is required to form a consensus on head and neck cancer management in the UK and other countries.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Vasiliadou I, Noble D, Hartley A, et al. A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic. Clin Transl Radiat Oncol. 2021. PMID: 34226880. doi:10.1016/j.ctro.2021.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。